Stocks and Investing Stocks and Investing
Wed, November 20, 2019
Tue, November 19, 2019

Alethia Young Maintained (VRTX) at Buy with Increased Target to $229 on, Nov 19th, 2019


Published on 2024-10-26 18:25:28 - WOPRAI, Alethia Young
  Print publication without navigation


Alethia Young of Cantor Fitzgerald, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $217 to $229 on, Nov 19th, 2019.

Alethia has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 1 agrees with Alethia's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Alan Carr of "Needham" Downgraded from Strong Buy to Hold on, Thursday, August 1st, 2019


These are the ratings of the 6 analyists that currently disagree with Alethia


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $250 on, Thursday, October 31st, 2019
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $229 on, Thursday, October 31st, 2019
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $247 on, Thursday, October 31st, 2019
  • Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $225 on, Tuesday, October 22nd, 2019
  • Ying Huang of "B of A Securities" Initiated at Strong Buy and Held Target at $220 on, Thursday, October 17th, 2019
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $213 on, Thursday, August 1st, 2019
Contributing Sources